YYFZBJS ameliorates colorectal cancer progression in Apc
Adenomatous Polyposis Coli Protein
Animals
Bacteroides fragilis
Bromodeoxyuridine
/ metabolism
Carcinogenesis
/ drug effects
Cell Proliferation
/ drug effects
Colorectal Neoplasms
/ drug therapy
Disease Models, Animal
Disease Progression
Drugs, Chinese Herbal
/ pharmacology
Gastrointestinal Microbiome
HCT116 Cells
Humans
Immunity
/ drug effects
Ki-67 Antigen
/ metabolism
Leukocytes, Mononuclear
/ drug effects
Lymph Nodes
/ drug effects
Mice
Mice, Inbred C57BL
Mucous Membrane
/ drug effects
Proliferating Cell Nuclear Antigen
/ metabolism
RNA, Messenger
/ genetics
Spleen
/ drug effects
T-Lymphocytes, Helper-Inducer
/ drug effects
T-Lymphocytes, Regulatory
/ drug effects
ApcMin/+ mice
Colorectal Cancer
Fecal microbiota transplantation
Gut microbiota
Immune
Regulatory T cell
Traditional Chinese herb medicine
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
16 07 2020
16 07 2020
Historique:
received:
11
10
2019
accepted:
11
05
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
12
8
2021
Statut:
epublish
Résumé
Progression of Colorectal cancer (CRC) is influenced by single or compounded environmental factors. Accumulating evidence shows that microbiota can influence the outcome of cancer immunotherapy. T cell, one of the main populations of effector immune cells in antitumor immunity, has been considered as a double-edged sword during the progression of CRC. Our previous studies indicate that traditional Chinese herbs (TCM) have potential anticancer effects in improving quality of life and therapeutic effect. However, little is known about the mechanism of TCM formula in cancer prevention. Here, we used C57BL/6 J Apc We report herein, YYFZBJS treatment blocked tumor initiation and progression in Apc In conclusion, we demonstrated that gut microbiota and Treg were involved in CRC development and progression, and we propose YYFZBJS as a new potential drug option for the treatment of CRC. Video abstract.
Sections du résumé
BACKGROUND
Progression of Colorectal cancer (CRC) is influenced by single or compounded environmental factors. Accumulating evidence shows that microbiota can influence the outcome of cancer immunotherapy. T cell, one of the main populations of effector immune cells in antitumor immunity, has been considered as a double-edged sword during the progression of CRC. Our previous studies indicate that traditional Chinese herbs (TCM) have potential anticancer effects in improving quality of life and therapeutic effect. However, little is known about the mechanism of TCM formula in cancer prevention.
METHODS
Here, we used C57BL/6 J Apc
RESULTS
We report herein, YYFZBJS treatment blocked tumor initiation and progression in Apc
CONCLUSIONS
In conclusion, we demonstrated that gut microbiota and Treg were involved in CRC development and progression, and we propose YYFZBJS as a new potential drug option for the treatment of CRC. Video abstract.
Identifiants
pubmed: 32677955
doi: 10.1186/s12964-020-00596-9
pii: 10.1186/s12964-020-00596-9
pmc: PMC7367414
doi:
Substances chimiques
Adenomatous Polyposis Coli Protein
0
Drugs, Chinese Herbal
0
Ki-67 Antigen
0
Proliferating Cell Nuclear Antigen
0
RNA, Messenger
0
Bromodeoxyuridine
G34N38R2N1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113Références
Evid Based Complement Alternat Med. 2017;2017:2906014
pubmed: 29348765
Mol Cancer Ther. 2014 Dec;13(12):3137-51
pubmed: 25205654
J Immunol Res. 2015;2015:860106
pubmed: 26146642
Proc Natl Acad Sci U S A. 2012 May 1;109(18):E1082-91
pubmed: 22451924
Nature. 2018 Jan 11;553(7687):208-211
pubmed: 29323293
Oncotarget. 2015 Sep 22;6(28):25975-87
pubmed: 26214021
EBioMedicine. 2019 Oct;48:301-315
pubmed: 31594750
mBio. 2019 Apr 2;10(2):
pubmed: 30940698
Cancer Cell. 2014 Aug 11;26(2):207-21
pubmed: 25065853
Int J Cancer. 2009 Aug 15;125(4):868-78
pubmed: 19408303
Cancer Lett. 2017 Sep 10;403:86-97
pubmed: 28602978
Eur J Immunol. 2015 Jun;45(6):1654-66
pubmed: 25754875
Oncoimmunology. 2015 Dec 21;5(4):e1118601
pubmed: 27141400
Biochem Biophys Res Commun. 2018 Sep 10;503(3):2152-2159
pubmed: 30119890
Am J Chin Med. 2017;45(4):637-666
pubmed: 28595500
Evid Based Complement Alternat Med. 2013;2013:957078
pubmed: 23533531
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Nat Med. 2017 Oct;23(10):1220-1225
pubmed: 28892065
Nat Commun. 2017 May 25;8:15129
pubmed: 28541302
Sci Rep. 2017 Aug 24;7(1):9373
pubmed: 28839202
Nat Commun. 2017 Apr 11;8:15004
pubmed: 28397782
Acta Histochem. 2016 Jun;118(5):544-52
pubmed: 27246286
Front Microbiol. 2019 Nov 12;10:2498
pubmed: 31798539
Asian Pac J Cancer Prev. 2013;14(6):3569-73
pubmed: 23886147
PLoS One. 2013 May 27;8(5):e63777
pubmed: 23723999
Microbiome. 2019 Mar 11;7(1):30
pubmed: 30853028
Mucosal Immunol. 2019 Jul;12(4):990-1003
pubmed: 31165767
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Br J Pharmacol. 2018 Apr;175(7):1085-1099
pubmed: 29352742
Front Cell Infect Microbiol. 2015 Mar 25;5:26
pubmed: 25859435
J Crohns Colitis. 2013 Dec;7(11):e558-68
pubmed: 23643066
Nat Commun. 2018 Aug 24;9(1):3437
pubmed: 30143634
Nature. 2013 Aug 8;500(7461):232-6
pubmed: 23842501
Int J Cancer. 2010 Jun 1;126(11):2635-43
pubmed: 19856313
Phytomedicine. 2018 May 15;44:187-203
pubmed: 29526584
Molecules. 2017 Sep 22;22(10):
pubmed: 28937627
Cell Physiol Biochem. 2017;41(4):1271-1284
pubmed: 28278498
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704
pubmed: 31554963
Cancer Immunol Immunother. 2014 Aug;63(8):807-19
pubmed: 24777614
J Agric Food Chem. 2018 May 2;66(17):4384-4393
pubmed: 29656647
Science. 2017 Aug 25;357(6353):806-810
pubmed: 28775213
Cell. 2019 Feb 21;176(5):1098-1112.e18
pubmed: 30794774
Immunity. 2018 Sep 18;49(3):515-530.e5
pubmed: 30231985
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12204-9
pubmed: 20566854
Cancer Res. 2006 Aug 1;66(15):7395-400
pubmed: 16885333
J Cell Physiol. 2015 Nov;230(11):2598-605
pubmed: 25913194
BMC Complement Altern Med. 2014 Aug 01;14:279
pubmed: 25085593
Cancer Immunol Immunother. 2018 Jul;67(7):1067-1077
pubmed: 29671006
Mol Carcinog. 2015 Oct;54(10):986-98
pubmed: 24797894
Science. 2011 Jan 21;331(6015):337-41
pubmed: 21205640
Cell. 2017 Jul 27;170(3):548-563.e16
pubmed: 28753429
Mol Med Rep. 2018 Apr;17(4):5320-5327
pubmed: 29393404
Nature. 2018 Dec;564(7735):268-272
pubmed: 30479382
Integr Cancer Ther. 2011 Sep;10(3):240-59
pubmed: 21964510
J Cancer Res Clin Oncol. 2019 May;145(5):1111-1122
pubmed: 30887153
Life Sci. 2018 Jan 1;192:160-165
pubmed: 29158050
Cell. 1993 Nov 19;75(4):631-9
pubmed: 8242739
Cell Death Dis. 2019 May 16;10(6):378
pubmed: 31097689
Gastroenterology. 2013 Apr;144(4):705-17
pubmed: 23415801
Curr Opin Gastroenterol. 2015 Mar;31(2):153-8
pubmed: 25594887
Cancer Metastasis Rev. 2010 Dec;29(4):569-79
pubmed: 20830504
Nature. 2013 Feb 21;494(7437):361-5
pubmed: 23376950
J Ethnopharmacol. 2015 Mar 13;162:7-13
pubmed: 25554637
Cell Mol Immunol. 2017 Jun;14(6):546-556
pubmed: 26972771
Clin Exp Immunol. 2018 Jan;191(1):32-41
pubmed: 28940183
Nat Med. 2019 Aug;25(8):1225-1233
pubmed: 31332392